QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

35,147 signal articles · 105 in last 24h · 178,672 total before filter · latest 1h ago

105last 24h

3126last 7d

510● bullish (7d)

311● bearish (7d)

227publishers

All Macro103 Earnings1820 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: CRSPSentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

Motley Fool79d agoneutral

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

CRSP ^GSPC ^IXIC

MarketBeat95d agoneutral

Blue Bird Q3 Earnings Call Highlights

MT Newswires96d agoneutral

Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says

Zacks96d agoneutral

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Zacks96d agoneutral

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

Zacks97d agobullish

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

Stocktwits97d agobullish

CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2

Simply Wall St.99d agoneutral

CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?

Motley Fool101d agobullish

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

CRSP MS NVDA ^GSPC

Zacks101d agoneutral

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

Motley Fool101d agoneutral

3 Stocks With the Most Upside by the End of 2026

Motley Fool103d agoneutral

3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside

Zacks103d agoneutral

Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline

Zacks103d agoneutral

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Barrons.com104d agoneutral

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

Zacks104d agobullish

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Motley Fool104d agobullish

Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.

CRSP NVDA SPCX TEM TSLA

Zacks107d agoneutral

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

Motley Fool109d agoneutral

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

Zacks111d agoneutral

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Simply Wall St.113d agobearish

Has CRISPR Therapeutics (CRSP) Fallen Far Enough To Look Undervalued?

Simply Wall St.114d agoneutral

Do CRISPR Therapeutics' (CRSP) EPS Projections Clarify Its Gene‑Editing Commercialisation Path?

Zacks114d agoneutral

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

Simply Wall St.114d agoneutral

CRISPR Therapeutics (CRSP) Slides For Six Days, Is The Stock Now Cheap?

Zacks115d agoneutral

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market

Trefis115d agoneutral

Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside

Zacks117d agoneutral

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Zacks121d agoneutral

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts

Motley Fool121d agobullish

3 Reasons to Buy CRISPR Therapeutics Stock

Zacks122d agobullish

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?